Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. Mar 1 2015;136(5):E359-386. 左婷婷,郑荣寿,曾红梅,张思维,陈万青.中国胃癌流行病学现状.中国肿瘤临床. 2017(01):52-58. Mommersteeg MC, Yu J, Peppelenbosch MP, Fuhler GM. Genetic host factors in Helicobacter pylori-induced carcinogenesis: Emerging new paradigms. Biochimica et biophysica acta. Nov 24 2017;1869(1):42-52. [4]Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lectureon Cancer Epidemiology and Prevention. Cancer Res, 1992, 52(24):6735~6740. [5]徐超,王健,郝素珍, 等.幽门螺杆菌感染促进胃癌SGC-7901细胞CD44和CD54的表达[J].中国热带医学,2016,(3):216-220. [6]Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC monographs on the evaluation of carcinogenic risks to humans. 1994;61:1-241. [7]Parkin DM. The global health burden of infection-associated cancers in the year 2002. International journal of cancer. Jun 15 2006;118(12):3030-3044. [8]Scotiniotis IA, Rokkas T, Furth EE, Rigas B, Shiff SJ. Altered gastric epithelial cell kinetics in Helicobacter pylori-associated intestinal metaplasia: implications for gastric carcinogenesis. International journal of cancer. Jan 15 2000;85(2):192-200. [9]杨舒,张雷.幽门螺旋杆菌致病与免疫机制的研究进展.中国病原生物学杂志. 2017(03):283-285+289. [10]钟晓刚,殷舞,黄顺荣.幽门螺旋杆菌与残胃癌发生的研究进展.世界华人消化杂志. 2010(30):3200-3203. [11]宋丹丹,李静.抗幽门螺杆菌治疗的研究现状.锦州医科大学学报. 2017(05):108-112. [12]Kalali B, Mejias-Luque R, Javaheri A, Gerhard M. H. pylori virulence factors: influence on immune system and pathology. Mediators of inflammation. 2014;2014:426309. [13]陈梅香,刘坤平,罗枫.结直肠癌原发灶及淋巴结转移灶中CD44 V6、E-cadherin蛋白表达变化及意义[J].山东医药,2014,5(18):1-3. [14]季涛, 等. "胃癌变过程中凋亡基因生存素及Bcl-2的表达与幽门螺杆菌感染相关性研究 中华医院感染学杂志,2015 (08): 1707-1709. [15]Liu YJ, Yan PS, Li J, Jia JF. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol. 2005; 11:6601-6606. [16]Yamaguchi A, Goi T, Seki K, Ohtaki N, Maehara M, Kobayashi T, Niimoto S, Katayama K,Hirose K, Nakagawara G, Matsukawa S. Clinical significance of combined immunohistochemical detection of CD44v and sialyl LeX expression for colorectal cancer patients undergoing curative resection. Oncology. 1998; 55:400-403. [17]丁秀杰,张睿.CD44基因在结肠癌组织中的表达及其意义[J].现代肿瘤医学,2014,22(6):1363-1364. [18]Yamaguchi A, Goi T, Yu J, Hirono Y, Ishida M, Iida A, Kimura T, Takeuchi K, Katayama K,Hirose K. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol. 2002; 79:230-235. [19]蔡迎彬,王岩,李可<sub>*</sub>.CD44在肠息肉和结直肠癌中的表达及相关性研究[J].中国医药导刊,2015,18(1):89-90. [20]Hong, R. L., et al. (1995). "Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas." Oncology 52(4): 334-339.
|